Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | DRD1 | P21728 | 3/20 | 0.50 |
| ▸ | DRD5 | P21918 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686484 | 0.87 | SLC6A4 (0.44) | DRD2ROCK2ROCK1 | |
| SCHEMBL11219877 | 0.81 | DRD2 (0.52) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL4684082 | 0.80 | MET (0.41) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL4684070 | 0.79 | MET (0.45) | — | |
| SCHEMBL4688203 | 0.79 | DRD3 (0.49) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL4687244 | 0.79 | DRD3 (0.49) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL3671316 | 0.77 | TRPV1 (0.47) | ROCK2ROCK1 | |
| SCHEMBL11230223 | 0.74 | DRD4 (0.53) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL9671500 | 0.74 | DRD2 (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL4687377 | 0.74 | MET (0.42) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | DRD2 1/4885DRD4 7/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.